vs
NEXSTAR MEDIA GROUP, INC.（NXST）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
NEXSTAR MEDIA GROUP, INC.的季度营收约是Revvity的1.7倍（$1.3B vs $772.1M），Revvity净利率更高（12.7% vs -12.9%，领先25.6%），Revvity同比增速更快（5.9% vs -13.4%），Revvity自由现金流更多（$161.8M vs $136.0M），过去两年Revvity的营收复合增速更高（9.0% vs 0.2%）
Nexstar Media Group, Inc.是美国上市传媒企业，总部设于得克萨斯州欧文、曼哈顿中城及芝加哥，1996年6月17日成立。作为美国规模最大的电视台运营商，集团在全美共拥有197家电视台，多数为美国四大广播电视网及MyNetworkTV附属台，覆盖从纽约到得州圣安杰洛等不同规模的市场。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
NXST vs RVTY — 直观对比
营收规模更大
NXST
是对方的1.7倍
$772.1M
营收增速更快
RVTY
高出19.3%
-13.4%
净利率更高
RVTY
高出25.6%
-12.9%
自由现金流更多
RVTY
多$25.8M
$136.0M
两年增速更快
RVTY
近两年复合增速
0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $-166.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 18.7% | 14.5% |
| 净利率 | -12.9% | 12.7% |
| 营收同比 | -13.4% | 5.9% |
| 净利润同比 | -168.6% | 3.9% |
| 每股收益（稀释后） | $-5.57 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NXSTRVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $1.2B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.5B | $729.4M | ||
| Q3 24 | $1.4B | $684.0M | ||
| Q2 24 | $1.3B | $691.7M | ||
| Q1 24 | $1.3B | $649.9M |
净利润NXSTRVTY
| Q4 25 | $-166.0M | $98.4M | ||
| Q3 25 | $70.0M | $46.7M | ||
| Q2 25 | $97.0M | $53.9M | ||
| Q1 25 | $108.0M | $42.2M | ||
| Q4 24 | $242.0M | $94.6M | ||
| Q3 24 | $187.0M | $94.4M | ||
| Q2 24 | $118.0M | $55.4M | ||
| Q1 24 | $175.0M | $26.0M |
毛利率NXSTRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率NXSTRVTY
| Q4 25 | 18.7% | 14.5% | ||
| Q3 25 | 14.6% | 11.7% | ||
| Q2 25 | 17.3% | 12.6% | ||
| Q1 25 | 17.8% | 10.9% | ||
| Q4 24 | 28.1% | 16.3% | ||
| Q3 24 | 24.5% | 14.3% | ||
| Q2 24 | 18.9% | 12.4% | ||
| Q1 24 | 21.4% | 6.8% |
净利率NXSTRVTY
| Q4 25 | -12.9% | 12.7% | ||
| Q3 25 | 5.8% | 6.7% | ||
| Q2 25 | 7.9% | 7.5% | ||
| Q1 25 | 8.8% | 6.4% | ||
| Q4 24 | 16.3% | 13.0% | ||
| Q3 24 | 13.7% | 13.8% | ||
| Q2 24 | 9.3% | 8.0% | ||
| Q1 24 | 13.6% | 4.0% |
每股收益（稀释后）NXSTRVTY
| Q4 25 | $-5.57 | $0.86 | ||
| Q3 25 | $2.14 | $0.40 | ||
| Q2 25 | $3.06 | $0.46 | ||
| Q1 25 | $3.37 | $0.35 | ||
| Q4 24 | $7.44 | $0.77 | ||
| Q3 24 | $5.27 | $0.77 | ||
| Q2 24 | $3.54 | $0.45 | ||
| Q1 24 | $5.16 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $280.0M | $919.9M |
| 总债务越低越好 | $6.3B | — |
| 股东权益账面价值 | $2.1B | $7.3B |
| 总资产 | $10.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 3.07× | — |
8季度趋势，按日历期对齐
现金及短期投资NXSTRVTY
| Q4 25 | $280.0M | $919.9M | ||
| Q3 25 | $236.0M | $931.4M | ||
| Q2 25 | $234.0M | $991.8M | ||
| Q1 25 | $253.0M | $1.1B | ||
| Q4 24 | $144.0M | $1.2B | ||
| Q3 24 | $181.0M | $1.2B | ||
| Q2 24 | $146.0M | $2.0B | ||
| Q1 24 | $237.0M | $1.7B |
总债务NXSTRVTY
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.4B | — | ||
| Q2 25 | $6.4B | — | ||
| Q1 25 | $6.5B | — | ||
| Q4 24 | $6.5B | — | ||
| Q3 24 | $6.7B | — | ||
| Q2 24 | $6.8B | — | ||
| Q1 24 | $6.8B | — |
股东权益NXSTRVTY
| Q4 25 | $2.1B | $7.3B | ||
| Q3 25 | $2.3B | $7.4B | ||
| Q2 25 | $2.3B | $7.6B | ||
| Q1 25 | $2.2B | $7.6B | ||
| Q4 24 | $2.3B | $7.7B | ||
| Q3 24 | $2.2B | $7.9B | ||
| Q2 24 | $2.3B | $7.9B | ||
| Q1 24 | $2.3B | $7.8B |
总资产NXSTRVTY
| Q4 25 | $10.8B | $12.2B | ||
| Q3 25 | $11.2B | $12.1B | ||
| Q2 25 | $11.3B | $12.4B | ||
| Q1 25 | $11.4B | $12.4B | ||
| Q4 24 | $11.5B | $12.4B | ||
| Q3 24 | $11.7B | $12.8B | ||
| Q2 24 | $11.8B | $13.4B | ||
| Q1 24 | $11.9B | $13.4B |
负债/权益比NXSTRVTY
| Q4 25 | 3.07× | — | ||
| Q3 25 | 2.78× | — | ||
| Q2 25 | 2.83× | — | ||
| Q1 25 | 2.89× | — | ||
| Q4 24 | 2.89× | — | ||
| Q3 24 | 3.02× | — | ||
| Q2 24 | 2.99× | — | ||
| Q1 24 | 2.93× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $190.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $136.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 10.6% | 21.0% |
| 资本支出强度资本支出/营收 | 4.2% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $743.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流NXSTRVTY
| Q4 25 | $190.0M | $182.0M | ||
| Q3 25 | $117.0M | $138.5M | ||
| Q2 25 | $247.0M | $134.3M | ||
| Q1 25 | $337.0M | $128.2M | ||
| Q4 24 | $411.0M | $174.2M | ||
| Q3 24 | $387.0M | $147.9M | ||
| Q2 24 | $176.0M | $158.6M | ||
| Q1 24 | $276.0M | $147.6M |
自由现金流NXSTRVTY
| Q4 25 | $136.0M | $161.8M | ||
| Q3 25 | $87.0M | $120.0M | ||
| Q2 25 | $218.0M | $115.5M | ||
| Q1 25 | $302.0M | $112.2M | ||
| Q4 24 | $376.0M | $149.8M | ||
| Q3 24 | $358.0M | $125.6M | ||
| Q2 24 | $139.0M | $136.6M | ||
| Q1 24 | $232.0M | $129.7M |
自由现金流率NXSTRVTY
| Q4 25 | 10.6% | 21.0% | ||
| Q3 25 | 7.3% | 17.2% | ||
| Q2 25 | 17.7% | 16.0% | ||
| Q1 25 | 24.5% | 16.9% | ||
| Q4 24 | 25.3% | 20.5% | ||
| Q3 24 | 26.2% | 18.4% | ||
| Q2 24 | 11.0% | 19.7% | ||
| Q1 24 | 18.1% | 20.0% |
资本支出强度NXSTRVTY
| Q4 25 | 4.2% | 2.6% | ||
| Q3 25 | 2.5% | 2.6% | ||
| Q2 25 | 2.4% | 2.6% | ||
| Q1 25 | 2.8% | 2.4% | ||
| Q4 24 | 2.4% | 3.4% | ||
| Q3 24 | 2.1% | 3.3% | ||
| Q2 24 | 2.9% | 3.2% | ||
| Q1 24 | 3.4% | 2.7% |
现金转化率NXSTRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 1.67× | 2.97× | ||
| Q2 25 | 2.55× | 2.49× | ||
| Q1 25 | 3.12× | 3.03× | ||
| Q4 24 | 1.70× | 1.84× | ||
| Q3 24 | 2.07× | 1.57× | ||
| Q2 24 | 1.49× | 2.87× | ||
| Q1 24 | 1.58× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NXST
| Distribution Service | $704.0M | 55% |
| Advertising | $491.0M | 38% |
| Other | $78.0M | 6% |
| Corporate | $3.0M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
